Search Result
Results for "
Antifibrotic
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-145555
-
|
DWN12088
|
DNA/RNA Synthesis
|
Inflammation/Immunology
|
|
Bersiporocin is a prolyl-tRNA synthetase inhibitor. Bersiporocin has an IC50 of ≤100 nM for phosphoribosylpyrophosphate synthetase (PRS). Bersiporocin can be used for the research of antifibrotic .
|
-
-
- HY-N0136
-
|
(+)-Dihydroquercetin; (+)-Taxifolin
|
TNF Receptor
Autophagy
Tyrosinase
|
Inflammation/Immunology
|
|
Taxifolin ((+)-Dihydroquercetin) exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
-
- HY-100445
-
-
-
- HY-100445A
-
-
-
- HY-N0136A
-
|
(±)-Dihydroquercetin
|
Autophagy
Tyrosinase
|
Inflammation/Immunology
|
|
(±)-Taxifolin ((±)-Dihydroquercetin) is the racemate of Taxifolin. Taxifolin exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
-
- HY-N0136B
-
|
(-)-Dihydroquercetin
|
Tyrosinase
|
Inflammation/Immunology
|
|
(-)-Taxifolin is the less active enantiomer of Taxifolin. Taxifolin exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
-
- HY-176194
-
|
|
Collagen
c-Fms
PDGFR
Src
|
Inflammation/Immunology
|
|
Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model .
|
-
-
- HY-162137
-
|
|
Apoptosis
|
Inflammation/Immunology
|
|
Hepatoprotective agent-1 (compound 1b) is a hepatoprotective agenrt. Hepatoprotective agent-1 shows anti-inflammatory, antiapoptotic and antifibrotic effects .
|
-
-
- HY-122483
-
|
|
MMP
|
Inflammation/Immunology
Cancer
|
|
iethyl pyimDC is a collagen prolyl 4-hydroxylase (CP4H1) inhibitor inhibitor with the IC50 of 2.6μM. Diethyl pyimDC can be used for study of antifibrotic and antimetastatic .
|
-
-
- HY-N0136R
-
|
(+)-Dihydroquercetin (Standard); (+)-Taxifolin (Standard)
|
TNF Receptor
Reference Standards
Autophagy
Tyrosinase
|
Inflammation/Immunology
|
|
Taxifolin (Standard) is the analytical standard of Taxifolin. This product is intended for research and analytical applications. Taxifolin ((+)-Dihydroquercetin) exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
-
- HY-119582
-
|
|
MMP
|
Inflammation/Immunology
|
|
Safironil is an antifibrotic compound. Safironil is a competitive inhibitor of collagen protein synthesis. Safironil reduces liver fibrogenesis by inhibiting HSC activation .
|
-
-
- HY-161730
-
-
-
- HY-N0136S1
-
|
(±)-Dihydroquercetin-13C3
|
Autophagy
Tyrosinase
|
Inflammation/Immunology
|
|
(±)-Taxifolin-13C3 ((±)-Dihydroquercetin-13C3) is a derivative of (±)-Taxifolin, labeled with 13C3. (±)-Taxifolin is the racemate of Taxifolin. Taxifolin exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
-
- HY-103070
-
|
|
MMP
|
Inflammation/Immunology
|
|
PythiDC is a selective collagen prolyl 4-hydroxylase (CP4H1) inhibitor with an IC50 value of 4.0 μM. PythiDC can be used as a CP4H probe and also can be used for the development of a new class of antifibrotic and antimetastatic agents .
|
-
-
- HY-109083
-
|
GS-9674
|
FXR
Autophagy
|
Inflammation/Immunology
|
|
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .
|
-
-
- HY-19149
-
|
|
HIV
Apoptosis
|
Infection
Inflammation/Immunology
Cancer
|
|
Ro24-7429 is a potent and orally active HIV-1 transactivator protein Tat antagonist. Ro24-7429 is also a runt-related transcription factor 1 (RUNX1) inhibitor. Ro24-7429 has anti-HIV, antifibrotic and anti-inflammatory effects .
|
-
-
- HY-111432
-
|
|
Ras
|
Others
|
|
CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma .
|
-
-
- HY-147243
-
|
ANG-3070
|
VEGFR
PDGFR
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .
|
-
-
- HY-137464A
-
OATD-01
1 Publications Verification
|
Others
|
Inflammation/Immunology
|
|
OATD-01 is a highly potent, first-in-class, orally active and selective chitinase inhibitor with low nanomolar activity toward CHIT1 (hCHIT1,IC50=23 nM). OATD-01 shows excellect PK profile in multiple species and is selectivity against a panel of other off-targets. OATD-01 exhibits significant antifibrotic efficacy in vivo and can be used for pulmonary fibrosis (IPF) research .
|
-
-
- HY-163752
-
|
|
MAP3K
|
Metabolic Disease
|
|
CS17919 is a potent, selective and orally active ASK1 inhibitor with an IC50 of 22.52 nM. CS17919 shows anti-inflammatory and antifibrotic effects. CS17919 can be used for the study of metabolic-related kidney and liver diseases .
|
-
-
- HY-N0152
-
-
-
- HY-176737
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
TGF-β1/Smad-IN-1 (compound C9) is a potent TGF-β1/Smad inhibitor. TGF-β1/Smad-IN-1 inhibits the expression of fibrosis markers (α-SMA and COL1A1) induced by TGF-β1. TGF-β1/Smad-IN-1 shows antifibrotic effects. TGF-β1/Smad-IN-1 has the potential for the research of hepatic fibrosis .
|
-
-
- HY-162904
-
|
|
Mitochondrial Metabolism
|
Cardiovascular Disease
|
|
BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .
|
-
-
- HY-B0673S
-
|
AMR69-d5
|
TGF-beta/Smad
CCR
|
Inflammation/Immunology
Cancer
|
|
Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
|
-
-
- HY-N9942
-
|
|
Apoptosis
Autophagy
NF-κB
p38 MAPK
PI3K
Akt
mTOR
STAT
JAK
|
Inflammation/Immunology
Cancer
|
|
Physalin A is a biologically active withanolide. Physalin A shows anti-inflammatory, antifibrotic and ameliorative effects on autophagy in models of disc degeneration. Physalin A has antitumor activity and can induce apoptosis, ROS production and G2/M phase cell cycle arrest. Besides. Physalin A can significantly increase the activity of quinone reductase and increase the expression of detoxifying enzymesc .
|
-
-
- HY-162404
-
-
-
- HY-162405
-
-
-
- HY-W005379
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
DGM is an inhibitor of the TGF-β1/Smad signaling pathway with significant antifibrotic effects. DGM inhibits the epithelial-mesenchymal transition (EMT) process in alveolar epithelial cells and slows the progression of pulmonary fibrosis in vivo by reducing lung inflammation, improving lung function, and decreasing extracellular matrix (ECM) remodeling. DGM can be used in research on idiopathic pulmonary fibrosis (IPF) and EMT-related diseases .
|
-
-
- HY-15183
-
|
|
Collagen
|
Cancer
|
|
Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor, which can be used as an anti-fibrotic agent .
|
-
-
- HY-N6928
-
-
-
- HY-P4890
-
-
-
- HY-P4890A
-
-
-
- HY-101473
-
|
|
Integrin
|
Inflammation/Immunology
|
|
EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research .
|
-
-
- HY-101737
-
|
Norucholic acid; nor-UDCA
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
24-norursodeoxycholic acid (Norucholic acid) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties.
|
-
-
- HY-120268
-
|
|
SphK
|
Inflammation/Immunology
|
|
SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .
|
-
-
- HY-170540
-
-
-
- HY-15307A
-
|
KD025 mesylate; SLx-2119 mesylate
|
ROCK
|
Inflammation/Immunology
|
|
Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
|
-
-
- HY-101473A
-
|
|
Integrin
|
Cancer
|
|
EMD527040 (hydrochloride) is a highly potent and selective αvβ6 antagonist with anti-fibrotic activity. EMD527040 (hydrochloride) is used in the research of liver cancer and liver fibrosis .
|
-
-
- HY-15307
-
|
KD025; SLx-2119
|
ROCK
|
Inflammation/Immunology
Cancer
|
|
Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
|
-
-
- HY-124646
-
|
|
IRE1
|
Inflammation/Immunology
|
|
KIRA-7, an imidazopyrazine compound, binds the IRE1α kinase (IC50 of 110 nM) to allosterically inhibit its RNase activity. KIRA-7 has an anti-fibrotic effect .
|
-
-
- HY-120268A
-
|
|
SphK
|
Inflammation/Immunology
|
|
SLM6031434 hydrochloride is the hydrochloride salt form of SLM6031434 (HY-120268). SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .
|
-
-
- HY-P0256
-
-
-
- HY-148087
-
AZD5462
1 Publications Verification
|
RXFP Receptor
|
Cardiovascular Disease
|
|
AZD5462 is a RXFP1 modulator, can be used for heart failure research. RXFP1 is the cognate receptor for human relaxin, belongs to GPCR family 1c number with anti-fibrotic and anti-inflammatory properties .
|
-
-
- HY-W803134
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
E/Z-SIS3 free base exhibits an inhibitory efficacy against smad3, exhibits an anti-fibrotic and anti-inflammatory effect through a TGF-β/smad3 signaling pathway .
|
-
-
- HY-113926
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect .
|
-
-
- HY-N6928R
-
|
|
Toll-like Receptor (TLR)
Reference Standards
|
Metabolic Disease
Cancer
|
|
Mogroside III-E (Standard) is the analytical standard of Mogroside III-E. This product is intended for research and analytical applications. Mogroside III-E is a cucurbitane-type compound isolated from Siraitia grosvenorii, inhibits NO release, with anti-fibrotic activity .
|
-
-
- HY-P0256A
-
|
Apamine TFA
|
Potassium Channel
|
Neurological Disease
Inflammation/Immunology
|
|
Apamin TFA (Apamine TFA) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically selective blocker of Ca 2+-activated K + (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity .
|
-
-
- HY-112606
-
|
|
RXFP Receptor
|
Others
|
|
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM . ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
|
-
-
- HY-100775
-
|
Setogepram sodium; PBI-4050 sodium
|
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis . Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
-
- HY-100775A
-
|
Setogepram; PBI-4050
|
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
- HY-P1931
-
|
Uteroglobin(39-47)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Antiflammin-1 is an anti-inflammatory peptide 1 (MQMKKVLDS). Antiflammin-1 is a derivative of uteroglobin. Antiflammin-1 has anti-inflammatory and antifibrotic actions in bleomycin (HY-108345)-induced lung injury .
|
-
- HY-15307AR
-
|
|
ROCK
|
Inflammation/Immunology
Cancer
|
|
Belumosudil (mesylate) (Standard) is the analytical standard of Belumosudil (mesylate). This product is intended for research and analytical applications. Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
|
-
- HY-15307R
-
|
|
ROCK
|
Inflammation/Immunology
Cancer
|
|
Belumosudil (Standard) is the analytical standard of Belumosudil. This product is intended for research and analytical applications. Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
|
-
- HY-P4860
-
|
|
Akt
Gli
JNK
PKA
|
Metabolic Disease
|
|
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
|
-
- HY-P991363
-
|
|
Myosin
|
Inflammation/Immunology
|
|
AX-202 is a human monoclonal antibody (mAb) targeting S100A4. AX-202 has antifibrotic effects in the mouse Tsk-1 model. AX-202 can be used in Plaque psoriasis and Systemic scleroderma research .
|
-
- HY-137978
-
|
GNS561
|
Autophagy
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Ezurpimtrostat (compound 2-2) is a potent and orally active anti-fibrotic agent. Ezurpimtrostat can be used for the research of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases (extracted from patent WO2020048694 A1) .
|
-
- HY-N1482S1
-
|
|
Parasite
|
Inflammation/Immunology
|
|
Methyl palmitate-d31 is the deuterium labeled Methyl palmitate. Methyl palmitate, an acaricidal compound occurring in green walnut husks, inhibits phagocytic activity and immune response. Methyl palmitate also posseses anti-inflammatory and antifibrotic effects .
|
-
- HY-136657
-
SC-43
4 Publications Verification
|
SHP1
Phosphatase
STAT
Apoptosis
|
Cancer
|
|
SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects .
|
-
- HY-N1482S
-
|
|
Parasite
|
Inflammation/Immunology
|
|
Methyl palmitate- 13C16 is the 13C labeled Methyl palmitate. Methyl palmitate, an acaricidal compound occurring in green walnut husks, inhibits phagocytic activity and immune response. Methyl palmitate also posseses anti-inflammatory and antifibrotic effects .
|
-
- HY-N1482R
-
|
|
Parasite
Reference Standards
|
Inflammation/Immunology
|
|
Methyl palmitate (Standard) is the analytical standard of Methyl palmitate. This product is intended for research and analytical applications. Methyl palmitate, an acaricidal compound occurring in Lantana camara, inhibits phagocytic activity and immune response. Methyl palmitate also posseses anti-inflammatory and antifibrotic effects .
|
-
- HY-100495
-
FT011
1 Publications Verification
Asengeprast
|
MMP
|
Inflammation/Immunology
|
|
FT011 is an anti-fibrotic agent, reduces mRNA expression of collagens I and III and inhibits collagen synthesis . FT011 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-101737R
-
|
Norucholic acid (Standard); nor-UDCA (Standard)
|
Drug Derivative
Reference Standards
Others
|
Inflammation/Immunology
|
|
24-Norursodeoxycholic acid (Standard) is the analytical standard of 24-Norursodeoxycholic acid. This product is intended for research and analytical applications. 24-norursodeoxycholic acid (Norucholic acid) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties.
|
-
- HY-163825
-
-
- HY-P99351
-
|
Anti-MMP9 Reference Antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-15307S
-
|
KD025-d7; SLx-2119-d7
|
Isotope-Labeled Compounds
ROCK
|
Inflammation/Immunology
Cancer
|
|
Belumosudil-d7 (KD025-d7) is deuterium labeled Belumosudil. Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
|
-
- HY-137978A
-
|
GNS561 hydrochloride
|
Palmitoyl Protein Thioesterase (PPT)
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Ezurpimtrostat hydrochloride (compound 2-3) is a potent and orally active anti-fibrotic agent. Ezurpimtrostat hydrochloride reduces significantly the liver fibrosis in DEN (diethyl nitrosamine) cirrhotic rat model. Ezurpimtrostat hydrochloride can be used for the research of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases .
|
-
- HY-P0266B
-
|
Ac-SDKP acetate
|
Angiotensin-converting Enzyme (ACE)
|
Inflammation/Immunology
|
|
N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) acetate is a specific substrate for the N-terminal active site of angiotensin-converting enzyme (ACE). N-Acetyl-Ser-Asp-Lys-Pro acetate is a natural inhibitor of pluripotent hematopoietic stem cell proliferation. Anti-inflammatory and antifibrotic properties .
|
-
- HY-176218
-
|
|
Drug Derivative
|
Inflammation/Immunology
|
|
TTTE is a sulfone bischalcone derivative. TTTE has major anti-necrotic, anti-inflammatory and anti-fibrotic activities. TTTE exerts regulatory effects by downregulating key molecules such as Caspase-3, TNF-α, NF-κB and TGF-β. TTTE can be used in the study of liver injury .
|
-
- HY-145855
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis .
|
-
- HY-P10414A
-
|
KP1 (human) hydrochloride
|
TGF-beta/Smad
p38 MAPK
|
Inflammation/Immunology
|
|
Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
|
-
- HY-P10414
-
|
KP1 (human)
|
TGF-beta/Smad
p38 MAPK
|
Inflammation/Immunology
|
|
Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
|
-
- HY-116893
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Diethyl bipy55'DC is an inhibitor of collagen proline 4-hydroxylases (CP4Hs) with antifibrotic and anti-metastatic activities. Diethyl bipy55'DC can inhibit CP4H activity in cultured cells at concentrations that do not cause iron deficiency .
|
-
- HY-N0664
-
|
|
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Aucubin, an iridoid glucoside, is isolated from Plantago asiatica, Eucommia ulmoides, the leaves of Aucuba japonica and more recently from butterfly larva. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects .
|
-
- HY-B0673
-
Pirfenidone
Maximum Cited Publications
68 Publications Verification
AMR69
|
TGF-beta/Smad
CCR
|
Inflammation/Immunology
Cancer
|
|
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
|
-
- HY-N1548
-
|
|
DNA/RNA Synthesis
|
Inflammation/Immunology
|
|
Prunasin is an orally active cyanogenic glucoside and the main metabolite of Amygdalin (HY-N0190). Prunasin can specifically inhibit rat DNA polymerase β (IC50: 98 μM). Prunasin has anti-inflammatory and anti-fibrotic activities. Prunasin can be used in the research of diseases such as liver fibrosis .
|
-
- HY-116282P
-
|
|
Bacterial
|
Inflammation/Immunology
|
|
Dextran sulfate, high sulfate (MW 5000), a biopolymer, is a sulfated polysaccharide. Dextran sulfate, high sulfate (MW 5000) has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
-
- HY-116282I
-
|
DSS (MW>500000); DXS (MW>500000)
|
Apoptosis
HIV
|
Inflammation/Immunology
|
|
Dextran sulfate sodium salt (MW>500000) (DSS (MW>500000)) is a negatively charged sulfated polysaccharide. Dextran sulfate sodium salt has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate sodium salt can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
-
- HY-116282J
-
|
|
Bacterial
|
Inflammation/Immunology
|
|
Dextran sulfate, low sulfate (MW 5000), a biopolymer, is a sulfated polysaccharide. Dextran sulfate, low sulfate (MW 5000) has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
-
- HY-N0136S
-
|
(+)-Dihydroquercetin-d3; (+)-Taxifolin-d3
|
Isotope-Labeled Compounds
Autophagy
Tyrosinase
|
Inflammation/Immunology
|
|
Taxifolin-d3 is deuterium labeled Taxifolin. Taxifolin ((+)-Dihydroquercetin) exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
- HY-116282M
-
|
|
Bacterial
|
Inflammation/Immunology
|
|
Dextran sulfate, low sulfate (MW 40000), a biopolymer, is a sulfated polysaccharide. Dextran sulfate, low sulfate (MW 40000) has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
-
- HY-173483
-
|
|
Phosphodiesterase (PDE)
ERK
JNK
p38 MAPK
|
Inflammation/Immunology
|
|
ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. ATX inhibitor 26 inhibits cell migration and collagen gel contraction. ATX inhibitor 26 has significant anti-fibrotic effects, reducing collagen deposition in a Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis model .
|
-
- HY-161506
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
PDE1-IN-7 (Compound 13h) is a selective inhibitor of bPDE1 (IC50= 10 nM). PDE1-IN-7 exhibits significant anti-fibrotic effects in a BDL-induced liver fibrosis rat model. PDE1-IN-7 can be used for research in liver fibrosis .
|
-
- HY-135401
-
|
|
Discoidin Domain Receptor
|
Inflammation/Immunology
|
|
VU6015929 is a potent, selective and orally active dual discoidin domain receptor 1/2 (DDR1/2) inhibitor with IC50s of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production .
|
-
- HY-109083A
-
|
GS-9674 tromethamine
|
Autophagy
FXR
|
Metabolic Disease
|
|
Cilofexor tromethamine (GS-9674 tromethamine) is a nonsteroidal farnesene oxide receptor agonist with activity in improving markers of cholestasis and liver injury. Cilofexor tromethamine was shown to be well tolerated in patients without cirrhosis and resulted in significant improvements in liver biochemical parameters and cholestatic markers. Cilofexor tromethamine offers a potential inhibitory option for the management of primary sclerosing cholangitis .
|
-
- HY-N16399
-
|
|
Reactive Oxygen Species (ROS)
Cadherin
|
Cancer
|
|
Black tea extract is the extract of Black tea. Black tea extract prevents inorganic arsenic (iAs) induced ROS generation, inhibiting uncontrolled proliferation, epithelial to mesenchymal transition (EMT) and metastasis in HaCaT cells. Black tea extract has an anti-fibrotic activity. Black tea extract can be used for skin cancers research .
|
-
- HY-P0170
-
TB500
1 Publications Verification
|
Drug Derivative
Akt
P2X Receptor
|
Inflammation/Immunology
|
|
TB500 is a synthetic version of an active region of thymosin β4. TB500 exhibits anti-fibrotic and wound healing activities by inhibiting the Akt signaling pathway and binding to actin. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation .
|
-
- HY-100775R
-
|
Setogepram sodium (Standard); PBI-4050 sodium (Standard)
|
Reference Standards
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (sodium) (Standard) is the analytical standard of Fezagepras (sodium). This product is intended for research and analytical applications. Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis . Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
- HY-173041
-
|
|
Arginase
|
Inflammation/Immunology
|
|
Arginase inhibitor 9 (Compound 12a) is an arginase inhibitor with IC50 values of 9 μM and 55 μM for bovine and human arginase I, respectively. Arginase inhibitor 9 exhibits antioxidant activity and can scavenge free radicals. Additionally, Arginase inhibitor 9 can effectively regulate the levels of collagen and procollagen, exerting an anti-fibrotic effect .
|
-
- HY-149205
-
|
|
PI3K
ERK
|
Inflammation/Immunology
|
|
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy .
|
-
- HY-130242
-
|
|
Monoamine Oxidase
|
Inflammation/Immunology
|
|
PXS-5120A is a potent, irreversible fluoroallylamine inhibitor of Lysyl Oxidase-like 2/3 (LOXL2/3) with anti-fibrotic activity. PXS-5120A is >300-fold selective for LOXL2 (Ki of 83 nM; pIC50 of 8.4) over LOXL (pIC50 of 5.8) .
|
-
- HY-168567
-
|
|
RIP kinase
NF-κB
p38 MAPK
|
Inflammation/Immunology
|
|
RIPK2-IN-6 (Compound 15a) is an inhibitor for RIPK, that inhibits the phosphorylation of RIPK2, and thus inhibits the NF-κB and MAPK signaling pathways. RIPK2-IN-6 exhibits anti-inflammatory and anti-fibrotic activities in Dextran sodium sulfate (HY-116282C)-induced mice colitis models .
|
-
- HY-A0060
-
|
NKK 105
|
Lipoxygenase
|
Cancer
|
|
Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
|
-
- HY-169963
-
|
|
Phosphodiesterase (PDE)
|
Others
|
|
PDE1-IN-8 (Compound 3f) is the inhibitor for PDE1 with an IC50 of 11 nM. PDE1-IN-8 inhibits cAMP and cGMP signaling pathway, inhibits the differentiation and proliferation of cells into myofibroblast, and exhibits anti-fibrotic efficacy in Bleomycin (HY-17565)-induced rat pulmonary fibrosis model .
|
-
- HY-100775AR
-
|
Setogepram (Standard); PBI-4050 (Standard)
|
Reference Standards
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (Standard) is the analytical standard of Fezagepras. This product is intended for research and analytical applications. Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
- HY-N0152R
-
-
- HY-N4107
-
|
|
TGF-beta/Smad
|
Infection
Inflammation/Immunology
Cancer
|
|
Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .
|
-
- HY-14928
-
-
- HY-18938A
-
|
GS-4997 hydrochloride
|
Apoptosis
MAP3K
|
Cancer
|
|
Selonsertib hydrochloride (GS-4997 hydrochloride) is an orally bioavailable enzyme inhibitor with potential anti-inflammatory, anti-tumor and anti-fibrotic activities. Selonsertib hydrochloride blocks ASK1 phosphorylation and activation by binding to the catalytic kinase domain. Selonsertib hydrochloride prevents the production of inflammatory cytokines and reduces the expression of genes associated with fibrosis. Selonsertib hydrochloride inhibits excessive apoptosis and limits cell proliferation .
|
-
- HY-19796
-
|
Aramchol; C20-FABAC
|
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
|
|
Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
|
-
- HY-17002
-
|
IPD 1151T
|
Interleukin Related
|
Inflammation/Immunology
|
|
Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity .
|
-
- HY-P10720
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse is an activator of particulate guanylate cyclase B (pGC-B), which is highly expressed in endothelial cells, kidneys, and the heart. C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse can mediate a potent anti-fibrotic effect in human cardiac and renal fibroblasts by generating the second messenger cGMP .
|
-
- HY-168930
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
ATX inhibitor 25 (Compound 29) is an orally active Autotaxin inhibitor with an IC50 of 1.08 nM. ATX inhibitor 25 exhibits excellent in vitro metabolic stability, with a t1/2 of more than 170 minutes. In the bleomycin (HY-108345)-induced pulmonary fibrosis mouse model, orally administered ATX inhibitor 25 shows anti-fibrotic effects .
|
-
- HY-163536
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
TGF-β1/Smad3-IN-1 (Compound 5aa) is an inhibitor of the TGF-β1/Smad3 signaling pathway(IC50=1.07 μM). TGF-β1/Smad3-IN-1 possesses antifibrotic activity and oral potency .
|
-
- HY-14928A
-
-
- HY-N0664R
-
|
|
Reference Standards
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Aucubin (Standard) is the analytical standard of Aucubin. This product is intended for research and analytical applications. Aucubin, an iridoid glucoside, is isolated from Plantago asiatica, Eucommia ulmoides, the leaves of Aucuba japonica and more recently from butterfly larva. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects .
|
-
- HY-B0673R
-
|
AMR69 (Standard)
|
Reference Standards
TGF-beta/Smad
CCR
|
Inflammation/Immunology
Cancer
|
|
Pirfenidone (Standard) is the analytical standard of Pirfenidone. This product is intended for research and analytical applications. Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
|
-
- HY-134988
-
|
|
FXR
Phosphatase
Cytochrome P450
|
Inflammation/Immunology
|
|
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
|
-
- HY-174348
-
|
|
Epigenetic Reader Domain
|
Inflammation/Immunology
|
|
BRD4-IN-10 (Compound 31) is a selective BRD4 inhibitor with an IC50 of 13.5 nM. BRD4-IN-10 can exert anti-inflammatory and anti-fibrotic effects. BRD4-IN-10 also has good metabolic stability, pharmacokinetic properties and safety. BRD4-IN-10 can be used in the research of renal fibrosis diseases .
|
-
- HY-B0673S1
-
|
LYT-100; AMR69-d3
|
Isotope-Labeled Compounds
|
Others
|
|
Deupirfenidone-d3 is the deuterium labeled Pirfenidone (HY-B0673). Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
|
-
- HY-173504
-
|
|
Others
|
Inflammation/Immunology
|
|
Anti-inflammatory agent 101 (Compound C04) is an orally active anti-inflammatory agent. Anti-inflammatory agent 101 has significant anti-lipid accumulation, anti-inflammatory and anti-fibrotic activities. Anti-inflammatory agent 101 works by reducing fatty acid uptake, stimulating fatty acid oxidation and alleviating inflammation. Anti-inflammatory agent 101 can be used in the study of NASH and its related liver fibrosis .
|
-
- HY-A0060R
-
|
|
Lipoxygenase
|
Cancer
|
|
Malotilate (Standard) is the analytical standard of Malotilate. This product is intended for research and analytical applications. Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
|
-
- HY-160851
-
|
AK3287; AKEX0011
|
ASK1
p38 MAPK
|
Inflammation/Immunology
|
|
GDC-3280 (AK3287; AKEX0011) is an orally active compound based on Pirfenidone (HY-B0673)'s phenyl pyridone scaffold. GDC-3280 alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 MAPK pathway and regulating macrophage polarization. GDC-3280 exhibits anti-inflammatory and anti-fibrotic effects .
|
-
- HY-P10728
-
|
|
RXFP Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
B7-33 is a single-chain relaxin mimetic. B7-33 is a selective relaxin receptor 1 (RXFP1) agonist. B7-33 binds to RXFP1 and preferentially activates thepERK pathway over cAMP in cells (with RXFP1 expression). B7-33 is an anti-fibrotic agent. B7-33 has cardioprotective effects .
|
-
- HY-114366
-
|
|
CXCR
|
Others
|
|
BC-1485 is a small molecule inhibitor of Fibrosis-inducing E3 ligase 1 (FIEL1). BC-1485 protects PIAS4 from ubiquitin-mediated degradation. BC-1485 decreases α-SMA, BAL and CXCL1. BC-1485 ameliorates fibrotic lung injury in murine models .
|
-
- HY-100438
-
-
- HY-156523
-
|
|
MAP4K
|
Cancer
|
|
TNIK&MAP4K4-IN-1 (compound A-39) is a dual inhibitor of TNIK and MAP4K4/HGK with IC50s of 1.29 nM and <10 nM，respectively，in human hepaticstellate cell LX-2. TNIK&MAP4K4-IN-1 can be used for cancer and fibrosis inhibition .
|
-
- HY-N4107R
-
|
|
Reference Standards
TGF-beta/Smad
|
Infection
Inflammation/Immunology
Cancer
|
|
Phyllanthin (Standard) is the analytical standard of Phyllanthin. This product is intended for research and analytical applications. Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .
|
-
- HY-163777
-
|
|
Phosphodiesterase (PDE)
|
Others
Inflammation/Immunology
|
|
Talaroterphenyl A (compound 1) is a p-terphenyl derivative present in the mangrove sediment-derived fungus Talaromyces sp. SCSIO 41412, which exhibits phosphodiesterase 4 (PDE4) inhibitory activity (IC50=1.2 μM). Talaroterphenyl A also exhibits anti-inflammatory and anti-fibrotic activities, significantly reducing the mRNA levels of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β .
|
-
- HY-P2150
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
- HY-P3618
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
- HY-148808
-
|
RXC007
|
ROCK
|
Cancer
|
|
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
|
-
- HY-156119
-
|
|
Mixed Lineage Kinase
Necroptosis
|
Metabolic Disease
Cancer
|
|
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .
|
-
- HY-169940
-
|
|
HDAC
|
Inflammation/Immunology
|
|
Fibrostat (Compound 5n) is a selective HDAC6 inhibitor that exerts antifibrotic effects by inhibiting HDAC6 activity, with an IC50 value of 63 nM. It also exhibits good selectivity over HDAC1, HDAC3, HDAC5, HDAC8, HDAC10, and HDAC11. Fibrostat significantly downregulates fibrotic markers (fibronectin and collagen 1) in fibroblasts. Additionally, Fibrostat demonstrated no toxicity in rat-perfused heart and zebrafish larvae models. Fibrostat shows potential for research into fibrosis-related diseases .
|
-
- HY-162630
-
|
|
HDAC
|
Inflammation/Immunology
|
|
HDAC6-IN-44 (compound H10) is a selective HDAC6 inhibitor with an IC50 value of 8.97 nM. HDAC6-IN-44 can inhibit the idiopathic pulmonary fibrosis (IPF) phenotype and exhibits antifibrotic activity. Additionally, HDAC6-IN-44 reduces fibrogenesis in a bleomycin-induced pulmonary fibrosis mouse model and demonstrates good metabolic stability. HDAC6-IN-44 holds promise for research in the field of idiopathic pulmonary fibrosis .
|
-
- HY-146434
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
TGFβ-IN-2 is an orally active TGF-β inhibitor. TGFβ-IN-2 suppresses the TGF-β-induced protein expression of COL1A1, α-SMA, and p-Smad3 in vitro. TGFβ-IN-2 demonstrates excellent anti-fibrotic efficacy in Bleomycin (HY-108345)-induced pulmonary fibrosis model. TGFβ-IN-2 can be used for the study of pulmonary fibrosis .
|
-
- HY-P10984
-
|
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
FNIII14 is derived from the 14th fibronectin (FN) type III-like (FN-III) repeat of FN molecule. FNIII14 is capable of inhibiting cell adhesion to the extracellular matrix (ECM). FNIII14 induces a conformational change in β1-integrin from the active to the inactive form, and blocks integrin-mediated signaling. FNIII14 has anti-fibrotic, anti-cancer effect. FNIII14 can be used for research of metabolic diseases, organ fibrosis, and malignant tumors .
|
-
- HY-175516
-
|
|
FXR
PPAR
|
Inflammation/Immunology
|
|
dual FXR/PPARδ agonist-2 is a FXR/PPARδ dual agonist through hybridation of FXR agonist GW-4064 and PPARδ agonist GW-0742.dual FXR/PPARδ agonist-2 displays potent dual-target activities with a FXR agonistic EC50 of 12.28 nM and 69 % PPARδ activation at 100 nM. dual FXR/PPARδ agonist-2 shows anti-fibrotic effects in pulmonary fibrosis mouse model .
|
-
- HY-138995
-
|
|
Deubiquitinase
|
Others
|
|
IMP-1710 is a potent and selective deubiquitylating enzyme UCHL1 inhibitor with an IC50 value of 38 nM. IMP-1710 has antifibrotic activity. IMP-1710 is a UCHL1 probe to identify and quantify target proteins in intact human cells . IMP-1710 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. IMP-1710 can be used in the research of idiopathic pulmonary fibrosis .
|
-
- HY-N0671
-
|
Rhaponiticin
|
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
|
-
- HY-156397
-
|
|
AMPK
YAP
|
Cancer
|
|
HTH-02-006 is a NUAK2 inhibitor, with an IC50 value of 126 nM. HTH-02-006 inhibits NUAK2-mediated signaling by reducing phosphorylation of its substrate MYPT1 at S445 and downstream MLC. HTH-02-006 shows growth inhibitory efficacy in YAP-high cancer cells (HuCCT-1, SNU475). HTH-02-006 significantly suppresses YAP-induced hepatomegaly (reduced liver/body weight ratio) in TetO-YAP S127A transgenic mice and demonstrates significant anti-tumor efficacy in mice bearing HMVP2 prostate cancer allografts. HTH-02-006 can be used for the study of liver cancer and prostate cancer .
|
-
- HY-173488
-
|
|
NF-κB
HIF/HIF Prolyl-Hydroxylase
Keap1-Nrf2
|
Cancer
|
|
NF-κB/HIF-1α-IN-1 (compound 9c) is a potent blocker of the NF-κB activation pathway and demonstrates selective anti-fibrotic activity. NF-κB/HIF-1α-IN-1 shows no significant cytotoxicity in NCI tumor cell lines. In rat models. NF-κB/HIF-1α-IN-1 has been shown to effectively ameliorate liver fibrosis by inhibiting the expression levels of NF-κB and HIF-1α, while simultaneously inducing the activation of Nrf2 .
|
-
- HY-170839
-
|
|
TRP Channel
|
Inflammation/Immunology
|
|
TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor that can be used for the research of idiopathic pulmonary fibrosis. TRPV1-IN-3 affects the expression of fibrosis markers collagen I and α-SMA by inhibiting the TGF-β/Smads and MAPK pathways, thereby exerting antifibrotic activity in vitro (IC50=0.51 μM). TRPV1-IN-3 significantly inhibits collagen deposition in lung tissue, improves the alveolar structure, and also increases the survival rate of mice with pulmonary fibrosis induced by Bleomycin (HY-108345) .
|
-
- HY-N0311
-
|
|
Aldose Reductase
Topoisomerase
SOD
p38 MAPK
|
Neurological Disease
Inflammation/Immunology
|
|
Emodin-8-glucoside is an anthraquinone derivative that can be isolated from Aloe vera. Emodin-8-glucoside is the inhibitor for MAPK with an inhibition constant of 430.14 pM. Emodin-8-glucoside exhibits moderate inhibitory activity against rat lens aldose reductase (ALAR) and topoisomerases II with IC50s of 14.4 μM and 66 μM. Emodin-8-glucoside exhibits antioxidant, anti-inflammatory and anti-fibrotic activities. Emodin-8-glucoside can cross the blood brain barrier .
|
-
- HY-12403A
-
|
TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
|
-
- HY-P11297
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research .
|
-
- HY-173235
-
|
|
Galectin
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Galectin-3-IN-6 (Compound 12) is an orally active inhibitor of galectin-3 (Gal-3), with an IC50 value of 12 nM and a Kd value of 13 nM for Gal-3. In a mouse model of acute liver injury and fibrosis induced by CCl4, Galectin-3-IN-6 can significantly reduce the levels of fibrosis markers collagen-1 and α-smooth muscle actin (αSMA) by 64% and 71%, respectively, showing significant anti-fibrotic activity. Galectin-3-IN-6 can be used in the research of fibrotic diseases, cancer, and cardiovascular diseases .
|
-
- HY-N6985
-
|
|
Others
|
Cancer
|
|
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment[1][2].
|
-
- HY-N0671R
-
|
Rhaponiticin (Standard)
|
Reference Standards
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
|
-
- HY-18303
-
AMG-47a
3 Publications Verification
|
Src
VEGFR
p38 MAPK
JAK
|
Inflammation/Immunology
|
|
AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC50=0.2 nM). AMG-47a inhibits VEGF2, p38α, p38α, Jak3, MLR, and IL-2 with IC50 of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].
|
-
- HY-12403
-
|
TXA127; Angiotensin (1-7); Ang-(1-7)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-121246
-
|
AKF-PD
|
NF-κB
ERK
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
|
-
- HY-176274
-
-
- HY-169177
-
|
|
JNK
|
Inflammation/Immunology
|
|
JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC50s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .
|
-
- HY-N1482
-
|
|
Parasite
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Methyl palmitate is a naturally occurring fatty acid ester. Methyl palmitate is a potent inhibitor of ΙκB phosphorylation. Methyl palmitate modulates macrophage activity and down-regulates pro-inflammatory mediators such as TNF-α and nitric oxide (NO). Methyl palmitate possesses anti-inflammatory and antifibrotic effects. Methyl palmitate can inhibit LPS (HY-D1056)-induced Kupffer cells and rat peritoneal macrophages. Methyl palmitate is able to inhibit the phagocytic function of RAW cells. Methyl palmitate is antagonistic to muscarinic receptors. Methyl palmitate exerts cardioprotective effects against ischemia/reperfusion injury in vivo. Methyl palmitate is highly toxic against adult T. cinnabarinus .
|
-
- HY-121246R
-
|
|
Reference Standards
NF-κB
ERK
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Fluorofenidone (Standard) is the analytical standard of Fluorofenidone (AKF-PD) (HY-121246). This product is intended for research and analytical applications. Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
|
-
- HY-P3318
-
|
L-BOC2
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .
|
-
- HY-29268
-
|
|
Bacterial
Indoleamine 2,3-Dioxygenase (IDO)
NF-κB
Phosphodiesterase (PDE)
|
Infection
Inflammation/Immunology
Cancer
|
|
β-Carboline 1-carboxylic acid is a β-carboline alkaloid with anti-inflammatory, antifibrotic, antitumor and antibacterial activities. β-Carboline 1-carboxylic acid is the cAMP phosphodiesterase (IC50: 96 µM) and indoleamine 2, 3-dioxygenase (IDO) inhibitor. β-Carboline 1-carboxylic acid is cytotoxic to tumor cells. β-Carboline 1-carboxylic acid inhibits inflammation through the NF-κb/p65 pathway and can reverse epithelial-mesenchymal transition (EMT). In addition, β-Carboline 1-carboxylic acid has strong inhibitory activity against S. aureus (IC50: 47.70 μg/mL) and E. coli (IC50: 19.17 μg/mL) .
|
-
- HY-N0311R
-
|
|
Reference Standards
Aldose Reductase
Topoisomerase
SOD
p38 MAPK
|
Neurological Disease
Inflammation/Immunology
|
|
Emodin-8-glucoside (Standard) is the analytical standard of Emodin-8-glucoside. This product is intended for research and analytical applications. Emodin-8-glucoside is an anthraquinone derivative that can be isolated from Aloe vera. Emodin-8-glucoside is the inhibitor for MAPK with an inhibition constant of 430.14 pM. Emodin-8-glucoside exhibits moderate inhibitory activity against rat lens aldose reductase (ALAR) and topoisomerases II with IC50s of 14.4 μM and 66 μM. Emodin-8-glucoside exhibits antioxidant, anti-inflammatory and anti-fibrotic activities. Emodin-8-glucoside can cross the blood brain barrier .
|
-
- HY-12403R
-
|
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-121246S
-
|
AKF-PD-d3
|
Isotope-Labeled Compounds
NF-κB
ERK
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Fluorofenidone-d3 (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
|
-
- HY-B0766
-
|
SY801
|
Autophagy
Apoptosis
HBV
HCV
HSP
Reactive Oxygen Species (ROS)
Bcl-2 Family
Glutathione S-transferase
p38 MAPK
NF-κB
Microtubule/Tubulin
ERK
JNK
TNF Receptor
Interleukin Related
CDK
Cyclin G-associated Kinase (GAK)
mTOR
P-glycoprotein
Ferroptosis
|
Infection
Inflammation/Immunology
Cancer
|
|
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-116282M
-
|
|
Cell Assay Reagents
|
|
Dextran sulfate, low sulfate (MW 40000), a biopolymer, is a sulfated polysaccharide. Dextran sulfate, low sulfate (MW 40000) has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
-
- HY-116282P
-
|
|
Cell Assay Reagents
|
|
Dextran sulfate, high sulfate (MW 5000), a biopolymer, is a sulfated polysaccharide. Dextran sulfate, high sulfate (MW 5000) has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
-
- HY-116282I
-
|
DSS (MW>500000); DXS (MW>500000)
|
Cell Assay Reagents
|
|
Dextran sulfate sodium salt (MW>500000) (DSS (MW>500000)) is a negatively charged sulfated polysaccharide. Dextran sulfate sodium salt has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate sodium salt can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
-
- HY-116282J
-
|
|
Cell Assay Reagents
|
|
Dextran sulfate, low sulfate (MW 5000), a biopolymer, is a sulfated polysaccharide. Dextran sulfate, low sulfate (MW 5000) has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0256
-
-
- HY-P0256A
-
|
Apamine TFA
|
Potassium Channel
|
Neurological Disease
Inflammation/Immunology
|
|
Apamin TFA (Apamine TFA) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically selective blocker of Ca 2+-activated K + (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity .
|
-
- HY-P4860
-
|
|
Akt
Gli
JNK
PKA
|
Metabolic Disease
|
|
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
|
-
- HY-P0266B
-
|
Ac-SDKP acetate
|
Angiotensin-converting Enzyme (ACE)
|
Inflammation/Immunology
|
|
N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) acetate is a specific substrate for the N-terminal active site of angiotensin-converting enzyme (ACE). N-Acetyl-Ser-Asp-Lys-Pro acetate is a natural inhibitor of pluripotent hematopoietic stem cell proliferation. Anti-inflammatory and antifibrotic properties .
|
-
- HY-P10414A
-
|
KP1 (human) hydrochloride
|
TGF-beta/Smad
p38 MAPK
|
Inflammation/Immunology
|
|
Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
|
-
- HY-P0170
-
TB500
1 Publications Verification
|
Drug Derivative
Akt
P2X Receptor
|
Inflammation/Immunology
|
|
TB500 is a synthetic version of an active region of thymosin β4. TB500 exhibits anti-fibrotic and wound healing activities by inhibiting the Akt signaling pathway and binding to actin. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation .
|
-
- HY-P4890
-
-
- HY-P4890A
-
-
- HY-P1931
-
|
Uteroglobin(39-47)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Antiflammin-1 is an anti-inflammatory peptide 1 (MQMKKVLDS). Antiflammin-1 is a derivative of uteroglobin. Antiflammin-1 has anti-inflammatory and antifibrotic actions in bleomycin (HY-108345)-induced lung injury .
|
-
- HY-P10414
-
|
KP1 (human)
|
TGF-beta/Smad
p38 MAPK
|
Inflammation/Immunology
|
|
Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
|
-
- HY-149205
-
|
|
PI3K
ERK
|
Inflammation/Immunology
|
|
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy .
|
-
- HY-P10720
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse is an activator of particulate guanylate cyclase B (pGC-B), which is highly expressed in endothelial cells, kidneys, and the heart. C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse can mediate a potent anti-fibrotic effect in human cardiac and renal fibroblasts by generating the second messenger cGMP .
|
-
- HY-P10728
-
|
|
RXFP Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
B7-33 is a single-chain relaxin mimetic. B7-33 is a selective relaxin receptor 1 (RXFP1) agonist. B7-33 binds to RXFP1 and preferentially activates thepERK pathway over cAMP in cells (with RXFP1 expression). B7-33 is an anti-fibrotic agent. B7-33 has cardioprotective effects .
|
-
- HY-P2150
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
- HY-P3618
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
- HY-P10984
-
|
|
Integrin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
FNIII14 is derived from the 14th fibronectin (FN) type III-like (FN-III) repeat of FN molecule. FNIII14 is capable of inhibiting cell adhesion to the extracellular matrix (ECM). FNIII14 induces a conformational change in β1-integrin from the active to the inactive form, and blocks integrin-mediated signaling. FNIII14 has anti-fibrotic, anti-cancer effect. FNIII14 can be used for research of metabolic diseases, organ fibrosis, and malignant tumors .
|
-
- HY-12403A
-
|
TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
|
-
- HY-P11297
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research .
|
-
- HY-12403
-
Talfirastide
Maximum Cited Publications
12 Publications Verification
TXA127; Angiotensin (1-7); Ang-(1-7)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-P3318
-
|
L-BOC2
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .
|
-
- HY-12403R
-
|
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99351
-
|
Anti-MMP9 Reference Antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-P991363
-
|
|
Myosin
|
Inflammation/Immunology
|
|
AX-202 is a human monoclonal antibody (mAb) targeting S100A4. AX-202 has antifibrotic effects in the mouse Tsk-1 model. AX-202 can be used in Plaque psoriasis and Systemic scleroderma research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0136
-
-
-
- HY-N0136A
-
-
-
- HY-N0136B
-
-
-
- HY-N0152
-
-
-
- HY-N9942
-
-
-
- HY-N6928
-
-
-
- HY-N0664
-
|
|
Infection
Eucommia ulmoides Oliver
Iridoids
Neurological Disease
Classification of Application Fields
Terpenoids
Source classification
Eucommiaceae
Plants
Inflammation/Immunology
Disease Research Fields
|
Bacterial
|
|
Aucubin, an iridoid glucoside, is isolated from Plantago asiatica, Eucommia ulmoides, the leaves of Aucuba japonica and more recently from butterfly larva. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects .
|
-
-
- HY-N0136R
-
-
-
- HY-N6928R
-
-
-
- HY-N1482R
-
-
-
- HY-N1548
-
-
-
- HY-N16399
-
-
-
- HY-N0152R
-
-
-
- HY-N4107
-
-
-
- HY-N0664R
-
|
|
Eucommia ulmoides Oliver
Iridoids
Terpenoids
Source classification
Eucommiaceae
Plants
|
Reference Standards
Bacterial
|
|
Aucubin (Standard) is the analytical standard of Aucubin. This product is intended for research and analytical applications. Aucubin, an iridoid glucoside, is isolated from Plantago asiatica, Eucommia ulmoides, the leaves of Aucuba japonica and more recently from butterfly larva. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects .
|
-
-
- HY-N4107R
-
-
-
- HY-163777
-
|
|
Monophenols
Microorganisms
Source classification
Phenols
|
Phosphodiesterase (PDE)
|
|
Talaroterphenyl A (compound 1) is a p-terphenyl derivative present in the mangrove sediment-derived fungus Talaromyces sp. SCSIO 41412, which exhibits phosphodiesterase 4 (PDE4) inhibitory activity (IC50=1.2 μM). Talaroterphenyl A also exhibits anti-inflammatory and anti-fibrotic activities, significantly reducing the mRNA levels of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β .
|
-
-
- HY-N0671
-
-
-
- HY-N0311
-
-
-
- HY-12403A
-
-
-
- HY-N6985
-
-
-
- HY-N0671R
-
|
Rhaponiticin (Standard)
|
Stilbenes
Classification of Application Fields
Polygonaceae
Source classification
Rheum officinale Baill.
Phenols
Plants
Disease Research Fields
Cancer
|
Reference Standards
Apoptosis
|
|
Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
|
-
-
- HY-12403
-
-
-
- HY-N1482
-
-
-
- HY-N0311R
-
|
|
Quinones
other families
Anthraquinones
Source classification
Phenols
Polyphenols
Plants
|
Reference Standards
Aldose Reductase
Topoisomerase
SOD
p38 MAPK
|
|
Emodin-8-glucoside (Standard) is the analytical standard of Emodin-8-glucoside. This product is intended for research and analytical applications. Emodin-8-glucoside is an anthraquinone derivative that can be isolated from Aloe vera. Emodin-8-glucoside is the inhibitor for MAPK with an inhibition constant of 430.14 pM. Emodin-8-glucoside exhibits moderate inhibitory activity against rat lens aldose reductase (ALAR) and topoisomerases II with IC50s of 14.4 μM and 66 μM. Emodin-8-glucoside exhibits antioxidant, anti-inflammatory and anti-fibrotic activities. Emodin-8-glucoside can cross the blood brain barrier .
|
-
-
- HY-12403R
-
|
|
Natural Products
Source classification
Endogenous metabolite
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
|
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N0136S1
-
|
|
|
(±)-Taxifolin-13C3 ((±)-Dihydroquercetin-13C3) is a derivative of (±)-Taxifolin, labeled with 13C3. (±)-Taxifolin is the racemate of Taxifolin. Taxifolin exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
-
- HY-B0673S
-
|
|
|
Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
|
-
-
- HY-N1482S
-
|
|
|
Methyl palmitate- 13C16 is the 13C labeled Methyl palmitate. Methyl palmitate, an acaricidal compound occurring in green walnut husks, inhibits phagocytic activity and immune response. Methyl palmitate also posseses anti-inflammatory and antifibrotic effects .
|
-
-
- HY-B0673S1
-
|
|
|
Deupirfenidone-d3 is the deuterium labeled Pirfenidone (HY-B0673). Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
|
-
-
- HY-N1482S1
-
|
|
|
Methyl palmitate-d31 is the deuterium labeled Methyl palmitate. Methyl palmitate, an acaricidal compound occurring in green walnut husks, inhibits phagocytic activity and immune response. Methyl palmitate also posseses anti-inflammatory and antifibrotic effects .
|
-
-
- HY-15307S
-
|
|
|
Belumosudil-d7 (KD025-d7) is deuterium labeled Belumosudil. Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
|
-
-
- HY-N0136S
-
|
|
|
Taxifolin-d3 is deuterium labeled Taxifolin. Taxifolin ((+)-Dihydroquercetin) exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM . Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity .
|
-
-
- HY-121246S
-
|
|
|
Fluorofenidone-d3 (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-100495
-
FT011
1 Publications Verification
Asengeprast
|
|
Alkynes
|
|
FT011 is an anti-fibrotic agent, reduces mRNA expression of collagens I and III and inhibits collagen synthesis . FT011 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-138995
-
|
|
|
Alkynes
|
|
IMP-1710 is a potent and selective deubiquitylating enzyme UCHL1 inhibitor with an IC50 value of 38 nM. IMP-1710 has antifibrotic activity. IMP-1710 is a UCHL1 probe to identify and quantify target proteins in intact human cells . IMP-1710 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. IMP-1710 can be used in the research of idiopathic pulmonary fibrosis .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
